[1] Moake J L, Turner N A, Stathopoulos N A, et al. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. Clin Invest, 1986,78:1456-1461.
[2] Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood, 1996,87:4223-4234.
[3] Dong J F, Moake J L, Bernardo A, et al. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. Biol Chem, 2003,278:29633-29639.
[4] Fujikawa K, Suzuki H, McMullen B, et al. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood, 2001,98:1662-1666.
[5] Gerritsen H E, Robles R, Lammle B, et al. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood, 2001,98:1654-1661.
[6] Levy G G, Nichols W C, Lian E C, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature, 2001,413:488-494.
[7] Just S. Methodologies and clinical utility of ADAMTS-13 activity testing. Semin Thromb Hemost, 2010,36:82-90.
[8] Sadler J E, Moake J L, Miyata T, et al. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Edu Program, 2004:407-423.
[9] Tripodi A, Peyvandi F, Chantarangkul V, et al. Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). J Thromb Haemost, 2008,6:1534-1541.
[10] Claus R A, Bockmeyer C L, Budde U, et al. Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb Haemost, 2009,101:239-247.
[11] Bockmeyer C L, Claus R A, Budde U, et al. Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica, 2008,93:137-140.
[12] Martin K, Borgel D, Lerolle N, et al. Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med, 2007,35:2375-2382.
[13] Nguyen T C, Liu A, Liu L, et al. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica, 2007,92:121-124.
[14] Uemura M, Fujimura Y, Matsumoto M, et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost, 2008,99:1019-1029.
[15] Matsuyama T, Uemura M, Ishikawa M, et al. Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. Alcohol Clin Exp Res, 2007,31:S27-35.
[16] Uemura M, Matsuyama T, Ishikawa M, et al. Decreased activity of plasma ADAMTS13 may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. Alcohol Clin Exp Res, 2005,29:264S-271S.
[17] Hugenholtz GC, Adelmeijer J, Meijers JC, et al. An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome. Hepatology, 2013,58:752-761.
[18] Bernardo A, Ball C, Nolasco L, et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood, 2004,104:100-106.
[19] Ferro D, Quintarelli C, Lattuada A, et al. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology, 1996,23:1377-1383.
[20] Schorer AE, Moldow CF, Rick M E. Interleukin 1 or endotoxin increases the release of von Willebrand factor from human endothelial cells. Br J Haematol, 1987,67:193-197.
[21] Kume Y, Ikeda H, Inoue M, et al. Hepatic stellate cell damage may lead to decreased plasma ADAMTS13 activity in rats. FEBS letters, 2007,581:1631-1634.
[22] Matsumoto M, Kawa K, Uemura M, et al. Prophylactic fresh frozen plasma may prevent development of hepatic VOD after stem cell transplantation via ADAMTS13-mediated restoration of von Willebrand factor plasma levels. Bone Marrow Transplant. 2007,40:251-259.
[23] Reiter RA, Varadi K, Turecek PL, et al. Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation. Thromb Haemost, 2005,93:554-558.
[24] Clifford BD, Donahue D, Smith L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology, 1995,21:613-619.
[25] Hsieh MY, Dai CY, Lee LP, et al. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C. J Clin Pathol, 2008,61:333-337.
[26] Lenzi M, Bellentani S, Saccoccio G, et al. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut, 1999,45:435-441.
[27] Ono T, Mimuro J, Madoiwa S, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood, 2006,107:528-534.
[28] Djamiatun K, van der Ven AJ, de Groot PG, et al. Severe dengue is associated with consumption of von Willebrand factor and its cleaving enzyme ADAMTS-13. PLoS Negl Trop Dis, 2012,6:e1628.
[29] De Filippis V, Lancellotti S, Maset F, et al. Oxidation of Met1606 in von Willebrand factor is a risk factor for thrombotic and septic complications in chronic renal failure. Biochem J, 2012,442:423-432. |
